Reflux is one of the most common reasons people self-treat, and the medicines involved are among the most familiar in the pharmacy. That very ordinariness is the risk: a reflux service can become an endless PPI refill line that never asks whether the symptoms are still reflux, still need treating, or were something more serious all along. Here is how to build one that treats reflux without ignoring what hides behind it.
Why reflux suits telehealth
Gastro-oesophageal reflux disease (GORD) and everyday heartburn are common, recognisable and largely managed with lifestyle measures and acid suppression — a good fit for remote care. Patients often know their triggers and want convenient access to effective treatment and advice.
The commercial model is a light subscription or managed supply, but as with allergy, much of the treatment is available over the counter. So the service earns its place through assessment, safety and review — spotting the cases that are not simple reflux and preventing unthinking long-term use — not merely by posting omeprazole.
The treatment ladder
Reflux treatment steps up from self-care to medicines:
- Lifestyle measures — weight, trigger foods, meal timing, alcohol and smoking — genuinely effective and the foundation.
- Antacids and alginates — such as Gaviscon, for symptomatic relief, widely available.
- Proton pump inhibitors (PPIs) — such as omeprazole or lansoprazole, the mainstay for GORD; lower-dose PPIs are available over the counter, higher doses are prescription-only.
- H2 antagonists — an alternative or add-on in some cases.
NICE guidance (NG184 / CKS) frames the ladder. Choice and duration depend on the clinical picture — prescriber discretion applies.
The red flags that change everything
The single most important skill in a reflux service is recognising alarm symptoms that are not to be treated as simple heartburn. These point toward something needing urgent investigation, and NICE is explicit that some warrant referral, including under a suspected-cancer pathway.
They include difficulty or pain swallowing, unintentional weight loss, persistent vomiting, evidence of gastrointestinal bleeding (such as black stools or vomiting blood), a new onset of symptoms in older patients, or an abdominal mass. Any of these takes the patient out of the remote treatment pathway and toward prompt assessment — not another course of PPI.
Reflux medicines are cheap and familiar, so the temptation is to strip the assessment back to a checkout. That is exactly backwards: the clinical value of a reflux service is in what the assessment catches — the alarm symptoms that are not simple heartburn, and the long-term PPI use that should have been reviewed.
The long-term PPI problem
PPIs are effective and generally well tolerated, which is exactly why they get taken indefinitely without review. Good practice is to use the lowest effective dose, review the ongoing need, and step down or stop where appropriate rather than repeating forever. Long-term use is sometimes clinically justified, but it should be a considered decision, not a default.
A reflux service therefore has to build review into supply: is this still needed, at this dose, and has anything changed? A service that refills PPIs endlessly with no review is doing the patient a disservice and storing up questions it cannot answer. Tie the review cadence to your clinical SOPs.
Difficulty swallowing, weight loss, persistent vomiting, signs of bleeding — these are not heartburn to be medicated. They take the patient out of the remote pathway and toward prompt investigation, sometimes on a suspected-cancer referral.
When to investigate rather than treat
Beyond the acute red flags, some patterns call for investigation rather than continued empirical treatment: symptoms that do not respond to adequate treatment, that keep relapsing when medication stops, or that persist despite a reasonable trial. These may need endoscopy or testing for Helicobacter pylori, which sit beyond a routine remote supply service.
Knowing when to stop treating and start investigating — and referring accordingly — is part of safe practice. Document the reasoning. The service's credibility rests on treating what it should and escalating what it should not keep managing.
Building the service
Operationally, reflux is a high-volume, mostly-stable pathway with a critical triage overlay: the assessment must reliably surface alarm symptoms and review long-term use, not just take an order. That overlay is the difference between a safe service and a refill machine, and it sits on the usual regulated spine of identity, prescriber governance and dispensing. Our launch checklist covers the sequence.
Because the medicines are cheap and familiar, the temptation to strip the assessment back is real — and precisely the wrong move. The clinical value is in what the assessment catches.
How PExpo supports a reflux launch
PExpo provides the regulated layer — registered dispensing, prescriber governance, pharmacovigilance and the patient record — so a brand can launch a reflux service on a compliant base, with the red-flag triage and review discipline that keep it safe built into the infrastructure.
You bring the brand and the funnel; the higher-risk clinical judgement is handled by an operator that runs it routinely. See our brand model and pricing.
Acid reflux rewards operators who build triage and review into supply rather than running a PPI refill line: treat straightforward reflux, catch the red flags for urgent referral, avoid indefinite unreviewed use, and investigate what does not respond. See our launch checklist and brand model for the operational detail.
Frequently asked questions
Can you get omeprazole or other PPIs online in the UK?
Yes. Lower-dose PPIs are available over the counter and higher doses are prescription-only, so a service manages reflux with advice and acid suppression under assessment. It should screen for alarm symptoms, use the lowest effective dose, and review long-term use rather than refilling indefinitely. Prescriber discretion applies.
What reflux symptoms are red flags?
Difficulty or pain swallowing, unintentional weight loss, persistent vomiting, signs of gastrointestinal bleeding such as black stools or vomiting blood, new symptoms in older patients, or an abdominal mass. NICE advises these need prompt assessment, sometimes via a suspected-cancer pathway, rather than continued heartburn treatment.
Is long-term PPI use a problem?
PPIs are effective and often well tolerated, but they are frequently taken indefinitely without review. Good practice is the lowest effective dose, periodic review of ongoing need, and stepping down or stopping where appropriate. Long-term use can be justified, but it should be a considered clinical decision, not a default refill.
